Drugs Made In America Acquisition Corp. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Roger Bendelac and CFO Saleem Elmasri issued standard Sarbanes-Oxley Section 302 and 906 certifications on August 14, 2026 for the quarterly period ended June 30, 2026. Both officers certified that the 10-Q fairly presents the company's financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud disclosures are mentioned.
Why this rating
Boilerplate SOX certifications; mandatory quarterly filing exhibit. No operational, financial, or strategic substance disclosed.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.